The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
4h
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US
AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.
Investing.com -- AstraZeneca (NASDAQ:AZN) said on Tuesday it has received European Union approval for Saphnelo (anifrolumab) ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients ...
After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
Zacks Investment Research on MSN
AstraZeneca (AZN) rises as market takes a dip: Key facts
In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...
AstraZeneca today announced a strategic regional collaboration with the Middle East North Africa Committee for Treatment and ...
The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback